ENHANCED PRODUCTION OF HIV-1 PROTEASE IN E COLI

Award Information
Agency:
Department of Health and Human Services
Branch
n/a
Amount:
$50,000.00
Award Year:
1989
Program:
SBIR
Phase:
Phase I
Contract:
n/a
Agency Tracking Number:
11449
Solicitation Year:
n/a
Solicitation Topic Code:
n/a
Solicitation Number:
n/a
Small Business Information
Tbc Research Laboratories
950 Boston Ave, Longmont, CO, 80501
Hubzone Owned:
N
Socially and Economically Disadvantaged:
N
Woman Owned:
N
Duns:
n/a
Principal Investigator:
() -
Business Contact:
() -
Research Institution:
n/a
Abstract
HUMAN IMMUNODEFICIENCY VIRUS TYPE I (HIV-1) IS THE ETIOLOGICAGENT OF ACQUIRED IMMUNE DEFICIENCY SYNDROME (AIDS). THIS PROJECT'S LONG-TERM OBJECTIVE IS TO STUDY THE ACTION OF THE HIV-1 PROTEASE TO DEVELOP SPECIFIC PROTEASE INHIBITORS THAT MIGHT BE ABLE TO HALT THE VIRAL REPLICATION. THIS STUDY IS POSSIBLE ONLY WITH THE AVAILABILITY OF LARGE QUANTITIES OF BIOLOGICALLY ACTIVE HIV-1 PROTEASE. PHASE I EFFORTS WILL DEVELOP A RECOMBINANT DNA SYSTEM TO PRODUCE THE PROTEASE. THE APPROACH TO BE USED WILL INVOLVE THE ASSEMBLY OF A SYNTHETIC GENE CODING FOR THE HIV-1 PROTEASE. THE GENE WILL BE CLONED INTO A PLASMID AND EXPRESSED IN ESCHERICHIA COLI. THE PRODUCTION LEVEL OF THE GENE PRODUCT WILL BE OPTIMIZED SO THAT THE PROTEASE CAN BE ECONOMICALLY PRODUCED. HIGH-LEVEL EXPRESSION OF THE PROTEASE WILL ENABLE PHASE II RESEARCH TO FOCUS ON THE E. COLI FERMENTATION SCALE-UP, PURIFICATION, AND RENATURATION OF THE PROTEASE TO YIELD BIOLOGICALLY ACTIVE HIV-1 PROTEASE.

* information listed above is at the time of submission.

Agency Micro-sites

US Flag An Official Website of the United States Government